In this MedPage Today video, Taylor Brooks, MD, of the Cleveland Clinic Cancer Institute, discusses real-world survival ...
In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...
At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...
Refractory dry eye in patients with systemic comorbidities can be challenging to manage because the underlying condition or ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
A new alloy combines the best of the refractory metals with cutting-edge engineering. Even these extremely tough metals can ...
The FDA approved epcoritamab plus R 2 on November 18 for the treatment of patients with relapsed or refractory FL. It also granted traditional approval for the treatment of relapsed or refractory FL ...
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for ...
Leyla O. Shune, MD, describes the available treatment options for patients with chronic graft-versus-host disease who are ...
Experts discuss the critical challenges in accessing innovative treatments for relapsed refractory multiple myeloma, ...
Delhi's Ghazipur Waste to Energy plant faced 108 days of shutdown due to maintenance issues, operating below capacity, with ...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback